HomeCompareGFNCP vs ABBV

GFNCP vs ABBV: Dividend Comparison 2026

GFNCP yields 69.56% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GFNCP wins by $980.6K in total portfolio value
10 years
GFNCP
GFNCP
● Live price
69.56%
Share price
$101.21
Annual div
$70.40
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.08M
Annual income
$289,209.16
Full GFNCP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GFNCP vs ABBV

📍 GFNCP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGFNCPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GFNCP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GFNCP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GFNCP
Annual income on $10K today (after 15% tax)
$5,912.46/yr
After 10yr DRIP, annual income (after tax)
$245,827.79/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GFNCP beats the other by $224,771.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GFNCP + ABBV for your $10,000?

GFNCP: 50%ABBV: 50%
100% ABBV50/50100% GFNCP
Portfolio after 10yr
$592.7K
Annual income
$156,990.46/yr
Blended yield
26.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GFNCP
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GFNCP buys
0
ABBV buys
0
No recent congressional trades found for GFNCP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGFNCPABBV
Forward yield69.56%3.06%
Annual dividend / share$70.40$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.3%40.6%
Portfolio after 10y$1.08M$102.3K
Annual income after 10y$289,209.16$24,771.77
Total dividends collected$925.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: GFNCP vs ABBV ($10,000, DRIP)

YearGFNCP PortfolioGFNCP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$17,677$6,976.70$11,550$430.00+$6.1KGFNCP
2$30,474$11,560.29$13,472$627.96+$17.0KGFNCP
3$51,289$18,681.81$15,906$926.08+$35.4KGFNCP
4$84,353$29,473.32$19,071$1,382.55+$65.3KGFNCP
5$135,696$45,437.98$23,302$2,095.81+$112.4KGFNCP
6$213,712$68,517.55$29,150$3,237.93+$184.6KGFNCP
7$329,825$101,153.70$37,536$5,121.41+$292.3KGFNCP
8$499,250$146,337.08$50,079$8,338.38+$449.2KGFNCP
9$741,835$207,637.47$69,753$14,065.80+$672.1KGFNCP
10$1,082,973$289,209.16$102,337$24,771.77+$980.6KGFNCP

GFNCP vs ABBV: Complete Analysis 2026

GFNCPStock

General Finance Corporation, a specialty rental services company, provides portable storage, modular space, and liquid containment solutions in North America and the Asia-Pacific regions. The company's portable storage products include storage containers for classroom equipment storage, construction equipment and tool storage, disaster shelters, landscaping sheds, recreational equipment storage, and retail inventory storage applications; and freight containers used in freight transportation. Its modular space products comprise office or portable building containers, ground level offices, and modular buildings and offices for use in general administrative office spaces, military installations, workforce living accommodations, bank branches, classrooms/education, construction offices, day-care facilities, dormitories, general administrative office space, healthcare and rental facilities, retail space, and shelters. The company's liquid containment products consist of portable liquid storage tanks for well-site liquid containment needs, expansion/upgrade projects, highway construction/groundwater sewage, infrastructure projects, major industrial projects, mining pit pump works, municipal sewer and water projects, non-residential construction projects, pipeline construction and maintenance, and refinery turnarounds. It also provides steps, ramps, furniture, portable toilets, security systems, shelving, mud pumps, hoses, splitter valves, tee connectors, and other items used in connection with leased equipment. In addition, the company offers temporary prison holding cells, hoarding units, blast-resistant units, workforce living accommodations, temporary retail frontage units, and observatory units customized from storage containers, as well as shipping container modifications, specialty trailers and tanks, chassis, storm shelters, and trash hoppers. The company was founded in 2005 and is headquartered in Pasadena, California.

Full GFNCP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GFNCP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GFNCP vs SCHDGFNCP vs JEPIGFNCP vs OGFNCP vs KOGFNCP vs MAINGFNCP vs JNJGFNCP vs MRKGFNCP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.